^
Association details:
| Biomarker: | DDX41 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) + azacitidine (DNA methylation inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Favorable outcomes of DDX41-mutated myelodysplastic syndrome and low blast count acute myeloid leukemia treated with azacitidine ± lenalidomide
Published date:
08/25/2023
Excerpt:
In summary, our correlative molecular analysis of the ALLG MDS4 trial of AZA versus AZA+LEN in MDS/AML has identified that patients with DDX41 mutations are associated with favorable outcomes with either AZA or AZA+LEN supporting the use of this therapy in these patients.
DOI:
10.1002/jha2.767
Source:
Title:
1779 Favorable Outcomes of DDX41-Mutated MDS and Low Blast Count AML Treated with Azacitidine with or without Lenalidomide (ALLG MDS4 Trial)
Published date:
11/03/2022
Excerpt:
Best responses achieved in DDX41 mutated patients were complete remission (CR, n=1), marrow CR (n=1), hematologic improvement (HI, n=1), and stable disease (SD, n=2). Remarkably, of the 5 patients that received treatment (4 AZA, 1 AZA+LEN), the overall survival at 52 months (range 47–58) follow up was 100% (Figure 2)...our correlative molecular analysis of the ALLG MDS4 trial of AZA vs AZA+LEN in MDS/AML has identified, in addition to established molecular risk factors for inferior outcomes, that pts with DDX41 mutations are associated with highly favorable outcomes with either AZA or AZA+LEN.
DOI:
https://doi.org/10.1182/blood-2022-162880
